CD2 and inflammation: Recent studies in transgenic mice expressing human CD219 have demonstrated that treatment with the anti-human CD2 monoclonal antibody CB.2 in a metastatic colitis model attenuated intestinal inflammation and extended survival, underscoring the substantial role of CD2 in the onset and progression of UC (49).